Home › Follicular Lymphoma › California › Baldwin Park
Follicular Lymphoma clinical trials in Baldwin Park, CA
16 studies for Follicular Lymphoma are looking for participants at sites in and around Baldwin Park (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RecruitingPhase 2/3
- City of Hope - Duarte Cancer Center ( Site 1301), Duarte · 4 mi away
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- City of Hope, Duarte · 4 mi away
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
RecruitingPhase 2
- City of Hope Medical Center, Duarte · 4 mi away
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- City of Hope, Duarte · 4 mi away
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingPhase 2
- Research Site, Duarte · 4 mi away
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
- City of Hope Comprehensive Cancer Center, Duarte · 4 mi away
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
- City of Hope Comprehensive Cancer Center, Duarte · 4 mi away
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- City of Hope, Duarte · 4 mi away
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RecruitingPhase 1
- City of Hope, Duarte · 4 mi away
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- City of Hope, Duarte · 4 mi away
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RecruitingPhase 1
- City of Hope Medical Center, Duarte · 4 mi away
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RecruitingPhase 3
- City of Hope Comprehensive Cancer Center, Duarte · 4 mi away
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- City of Hope Medical Center, Duarte · 4 mi away
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RecruitingPhase 1/2
- City of Hope, Duarte · 4 mi away
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- City of Hope, Duarte · 4 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Duarte · 4 mi away
Follicular Lymphoma trials in other cities
- New York City, NY24 studies
- Milwaukee, WI19 studies
- Nashville, TN18 studies
- Houston, TX18 studies
- Boston, MA17 studies
- Seattle, WA16 studies
- Durham, NC15 studies
- Columbus, OH13 studies
- Salt Lake City, UT12 studies
- Chicago, IL12 studies
- San Antonio, TX12 studies
- Philadelphia, PA12 studies
Other studies in Baldwin Park
- Breast Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Colorectal Cancer38 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)32 studies
- Prostate Cancer31 studies
- Metastatic Cancer30 studies
- Myelodysplastic Syndromes26 studies
- Ovarian Cancer25 studies
- Lung Cancer24 studies
- Multiple Myeloma23 studies
- Stomach Cancer21 studies
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.